

# Drug Price Transparency Manufacturer Reporting Training Webinar

Drug Price Transparency Program Team  
Division of Financial Regulation  
Feb. 16, 2023



Department of Consumer  
and Business Services



# Agenda



**Annual price increase reporting**

**New drug reporting**

**iReg users and contacts**



**60-day price increase notice reporting**

**Correspondence and requests for information**



**Trade secret claims**

**Billings and assessments**



iReg is our reporting system



# Annual price increase reporting

## When to file?

- Reporting threshold:
  - Increase in weighted average wholesale acquisition cost (WAC) of **10 percent** or more, **AND**
  - WAC for drug is **\$100** or more for a 30-day supply (or course of treatment lasting less than one month).
- Due date: If required, 2022 reports are due **March 15, 2023**.
- **Example:** Drug Z costs \$500 during 2021. The price is increased to \$575 on May 1, 2022. The average price for 2022 is \$550.34 (120 days at \$500 and 245 days at \$575). The increase is 10 percent or more, so a report is required.

# Annual price increase reporting

- Start annual price increase filing.
- Enter filing year and National Drug Code (NDC).
- Enter trade name and chemical name if not populated.

Insurance iReg - Drug Prices - Annual Filings - Filings  
Entity Name: ENTITY NAME  
Home Drug Prices  
New Drugs Annual Filings Correspondence 60-Day  
Filings  
Details  
Show All  
10 records per page  
Create/Filing Date  
Showing 0 to 0 of 0 entries  
Create New Filing

New Drugs Annual Filings Correspondence 60-Day Billings  
Filings  
Details  
Start Annual Drug Filing  
Filing Year: \*  
NDC: \*  
Trade Name: \*  
Chemical Name: \*  
Next Cancel



# Annual price increase reporting

- Complete the report following our user guide.

New Drugs Annual Filings Correspondence 60-Day Billings Instruct

Filings  
Details

### Drug Price Increase Filing Details

Filing Status: In Progress

\* Filing Year:

\* NDC:

\* Trade Name:

\* Chemical Name:

Generic Name(s):

For the NDC:

\* Net Increase Percent:

\* Introductory Price:  Trade Secret?

\* Price on January 1st:

\* Price on December 31st:

\* Highest Wholesale Acquisition Cost (WAC):


\* Lowest Wholesale Acquisition Cost (WAC):

\* Average Wholesale Acquisition Cost (WAC):  Trade Secret?

\* Dosage:  Trade Secret?

# Annual price increase reporting

- Complete the report following our user guide.



The screenshot shows a web form with the following elements:

- A label "\* Date on Market:" followed by a text input field and a small calendar icon.
- A label "\* Increase factors:" followed by a large text area.
- To the right of the text area, the text "Trade Secret?" is displayed next to a yellow dropdown menu currently showing "Not Set".



**Increase factors compliance tip:** Report clear and specific information. If company did not use any drug comparisons for determining the price increase, clearly confirm in writing that no comparison was used *and* report what the company did use for setting the increased price.

# Annual price increase reporting

- Complete the report following our user guide.

R&D Costs Using:		Direct Costs:	
* International Public Funds:	<input type="text"/>	* Manufacturing:	<input type="text"/>
	Trade Secret? <span>Not Set</span> ▼		Trade Secret? <span>Not Set</span> ▼
* USA Federal Public Funds:	<input type="text"/>	* Marketing:	<input type="text"/>
	Trade Secret? <span>Not Set</span> ▼		Trade Secret? <span>Not Set</span> ▼
* All States Public Funds:	<input type="text"/>	* Distribution:	<input type="text"/>
	Trade Secret? <span>Not Set</span> ▼		Trade Secret? <span>Not Set</span> ▼
* All Local Public Funds:	<input type="text"/>	* Safety and Effectiveness:	<input type="text"/>
	Trade Secret? <span>Not Set</span> ▼		Trade Secret? <span>Not Set</span> ▼
* Public Funds Sources and Uses:	<input type="text"/>	* Total Sales Revenue:	<input type="text"/>
	Trade Secret? <span>Not Set</span> ▼		Trade Secret? <span>Not Set</span> ▼
		* Profit from Drug:	<input type="text"/>
			Trade Secret? <span>Not Set</span> ▼
		* Other Relevant Pricing Information:	<input type="text"/>
			Trade Secret? <span>Not Set</span> ▼

# Annual price increase reporting

- Complete the report following our user guide.

**Non US Prices:**

\*  We only sell in the US Trade Secret? Not Set ▾

	Country	Price
Country 1:	<input type="text"/>	<input type="text"/>
Country 2:	<input type="text"/>	<input type="text"/>
Country 3:	<input type="text"/>	<input type="text"/>
Country 4:	<input type="text"/>	<input type="text"/>
Country 5:	<input type="text"/>	<input type="text"/>
Country 6:	<input type="text"/>	<input type="text"/>
Country 7:	<input type="text"/>	<input type="text"/>
Country 8:	<input type="text"/>	<input type="text"/>
Country 9:	<input type="text"/>	<input type="text"/>
Country 10:	<input type="text"/>	<input type="text"/>

**5-Year Net Annual Increases:**

\* Trade Secret? Not Set ▾

	% Increase	
2022	<input type="text"/>	<input type="checkbox"/> Not on Market
2021	<input type="text"/>	<input type="checkbox"/> Not on Market
2020	<input type="text"/>	<input type="checkbox"/> Not on Market
2019	<input type="text"/>	<input type="checkbox"/> Not on Market
2018	<input type="text"/>	<input type="checkbox"/> Not on Market

**Patient Assistance Programs:**

10 ▾ records per page Search:

Program Name	Participant Count	Value of Assistance
No data available in table		

Showing 0 to 0 of 0 entries ← Prev

[Add Assistance Program](#)



# Annual price increase reporting

- Complete the report following our user guide.

**Add Assistance Program**

\* Program Name:

\* Program Type:

\* Number of Participants:  Trade Secret?

\* Value of Assistance:  Trade Secret?

\* Refills:  Trade Secret?


\* Time Period:  Trade Secret?

\* Eligibility Criteria:  Trade Secret?

\* Eligibility Verification Process:  Trade Secret?

# Annual price increase reporting

- Complete the report following our user guide.
- If a document is needed to explain a data element, click the “Attach New Document” button.
- Identify the section of the report or choose “Other Supporting Documentation.”
- The reason for the inclusion information will appear on the transparency site.



The screenshot shows a web form titled "Add Document" with a sub-header "Attach Supporting Document". The form contains the following fields and controls:

- Document Type:** A dropdown menu with the selected value "Other Supporting Documental" and a red asterisk indicating it is required.
- Reason for Inclusion:** A text area with the placeholder text "Description and reason for document" and a red asterisk.
- Document:** A file upload field with a "Choose File" button and the filename "20211208-D...-agenda.pdf" and a red asterisk.
- Trade Secret?:** A dropdown menu with the selected value "Not Set" and a red asterisk.

At the bottom of the form, there are two buttons: "Submit" (in blue) and "Cancel" (in grey).



# Annual price increase reporting

- Once completed, you will certify to submit the report.

**Documents:**

10 records per page Search:

Doc Type	Reason for Inclusion	TS?	Justification	Document
Patient Assistance Programs	Additional PAP information.	No		<a href="#">View Info</a> <a href="#">View Original</a>

Showing 1 to 1 of 1 entries ← Previous

[Attach New Document](#)

[Continue To Certification](#) [Save Progress](#) [Cancel](#) [Start/Open Correspondence](#) [Delete Filing](#)



When you view a submitted report, you will only have the link to its correspondence.

NDC:

Trade Name:

Chemical Name:

### Certification

Certifier's Name:

I, the undersigned authorized filer, hereby certify that the filing submitted complies with the applicable State law and regulations, Bulletins, filing requirements and reporting guidance set forth on the Department of Consumer and Business Services' web site. I further certify the filing is not false or misleading in any material respect and that I am authorized to sign and submit this certificate on behalf of the Company identified (hereinafter Company).

I understand that the Department of Consumer and Business Services will rely on this certificate and, should it be determined that this filing is materially false or misleading, appropriate action including civil penalties, as authorized by law, will be taken by the Department of Consumer and Business Services against the Company.

[Certify](#) [Cancel](#)

# Annual price increase reporting

## Tips and reminders:

- Reports for 2022 are due March 15, 2023.
- Only file reports that are required. See formula for average price and examples in user guide.
- Report the specific information requested.
- Report accurate and complete information.
- Delete in progress reports that are not required.
- If there are missing reports due in prior years, submit as soon as possible to avoid or reduce penalties.



# New specialty drug reporting

## When to file?

- Reporting threshold:
  - Price exceeds \$670 for a 30-day supply, or a course of treatment lasting less than 1 month.
- Due date: If required, due within 30 days of launch for sale in the U.S.
- If a drug meets the reporting threshold, report on each NDC being introduced to the U.S. market.

# New specialty drug reporting

- Start new specialty drug filing.
- Enter NDC, trade name, and chemical name.

Insurance iReg - Drug Prices - New Drugs - Filings  
Entity Name: ENTITY NAME

Home Drug Prices

New Drugs Annual Filings Correspondence 60-Day

Filings  
Details

Show All

10 records per page

Create/Filing Date

Showing 0 to 0 of 0 entries

Create New Filing

Home Drug Prices

New Drugs Annual Filings Correspondence 60-Day Billings

Filings  
Details

### Start New Drug Filing

NDC:  \*

Trade Name:  \*

Chemical Name:  \*

Next Cancel




**Reminder for generic drug reports:** Enter the trade name of the NDC being reported. Do not report the brand name of a competing product.



# New specialty drug reporting

- Complete the report following our user guide.



The screenshot shows a web form for drug reporting. It contains the following elements:

- \* Trade Name:** A text input field containing the placeholder text "Trade name".
- \* Chemical Name:** A text input field containing the placeholder text "Chemical name".
- \* Marketing Description:** A large text area for entering details.
- Trade Secret?:** A dropdown menu currently set to "Not Set".



## Compliance tip for marketing description:

Report marketing activities and the amounts spent and include:

- Direct-to-consumer marketing, such as paid advertising
- Marketing to promote the drug to physicians

Generic drugs: If drug is not marketed, tell us there is no marketing and no spending.

# New specialty drug reporting

- Complete the report following our user guide.

* Wholesale Acquisition Cost (WAC):	<input type="text"/>	Trade Secret?	Not Set <input type="button" value="v"/>
* Dosage:	<input type="text"/>	Trade Secret?	Not Set <input type="button" value="v"/>
* Pricing Methodology:	<input type="text"/>	Trade Secret?	Not Set <input type="button" value="v"/>



**Compliance tip for pricing methodology:** Report all major financial and nonfinancial factors that influenced the price.

Generic drugs: Provide comparison information *or* confirm no comparison was used and report what guided pricing.




# New specialty drug reporting

- Complete the report following our user guide.

\* FDA Priority or Breakthrough:

Acquisition Cost:  Trade Secret?

Required if the drug was acquired

Acquisition Date:   Trade Secret?

Required if the drug was acquired

 Report Acquisition Cost and Date *only* if applicable.

\* Estimated Avg. Number of Patients per Month:  Trade Secret?

Patients per Month Description:  Trade Secret?

# New specialty drug reporting

- Complete the report following our user guide.

**R&D Costs Using:**

\* International Public Funds:  Trade Secret? Not Set

\* USA Federal Public Funds:  Trade Secret? Not Set


\* All States Public Funds:  Trade Secret? Not Set

\* All Local Public Funds:  Trade Secret? Not Set

\* Public Funds Sources and Uses:

**Documents:**

10 records per page Search:

Doc Type	Reason for Inclusion	TS?	Justification	Document
FDA Priority or Breakthrough Designation	FDA information on breakthrough therapy.	No		<a href="#">View Info</a>  <a href="#">View Original</a>

Showing 1 to 1 of 1 entries ← Previous 1 Next →

[Attach New Document](#)

[Continue To Certification](#) [Save Progress](#) [Cancel](#)  
[Start/Open Correspondence](#) [Delete Filing](#)

# New specialty drug reporting

## Tips and reminders:

- Reports are due within 30 days of market availability.
- Report the specific information requested.
- Report accurate and complete information.
- Only file reports that are required.
- Delete in progress reports that are not required.
- If there are missing reports due in prior years, submit as soon as possible to avoid or reduce penalties.



# iReg users and contacts

- Manufacturers are responsible for keeping their company information up to date.
- Certain notices are only received by contacts, not users.
  - It is important to have the correct users as contacts.
- Make sure your email system is not blocking or quarantining communications from iReg (emails ending with “.gov”).

# iReg users and contacts

- Users: Each user may also have permissions for the type of reports processed. This allows the user to view, create, edit, or submit reports for specified categories.

The screenshot shows the 'Users' management page in the iReg system. The navigation bar includes 'Main', 'Users', and 'Contacts' tabs, with 'Users' selected. On the right, there are 'Instructions' and 'Log out' buttons. The left sidebar contains 'User List' (highlighted) and 'User Detail'. The main content area features a table with columns for Logon ID, First Name, Last Name, Email Address, and Phone Number. A single user entry is displayed with a radio button selected. Below the table, there are 'Add User', 'Edit User', and 'Remove User' buttons.

Logon ID	First Name	Last Name	Email Address	Phone Number
<input checked="" type="radio"/> FLASTNAX	First &	Last Name	rx.prices@dcbs.oregon.gov	503-947-7200



# iReg users and contacts

## Contacts: List of contacts receiving notices for accounts

The screenshot displays the iReg Contacts interface. The top navigation bar includes 'Main', 'Users', and 'Contacts' tabs, along with 'Instructions' and 'Log out' buttons. The left sidebar contains 'Contact List', 'Contact Detail', and 'Contact History' options. The main content area shows a 'What is a contact?' help link and a table with columns for 'Name Title' and 'Email Address'. A single contact is listed with the name 'First & Last Name, Title' and email 'rx.prices@dcbs.oregon.gov'. Below the table are 'Add Contact', 'Edit Contact', and 'Remove Contact' buttons.

A second screenshot shows the 'Contact History' view. It features a search bar and a 'Filter' button. The table below has columns for 'Date' and 'Subject'. The data rows are as follows:

Date	Subject
01/06/2022	TEST: Oregon Division of Financial Regulation iReg reporting system - Account Updated
01/05/2022	TEST: Oregon Division of Financial Regulation iReg reporting system - Account Updated
01/05/2022	TEST: Oregon Division of Financial Regulation iReg reporting system - Welcome

**i** Contact history shows prior iReg system notices sent.



# iReg users and contacts

Users: access permissions

For every account in iReg, there should be at least one user with the appropriate permissions to adjust contacts and users.

The screenshot displays the 'Application Access' configuration interface. It is divided into two main sections: 'Financial Regulation' and 'Drug Prices'. Each section has a list of permissions on the left and an 'Application Information' box on the right. At the bottom, there are 'Save' and 'Cancel' buttons.

**Application Access:**

**Financial Regulation**

- Registered Entities Administration
- Registered Entities Submission
- Registered Entities View

**Manage Users**

**Application Information:**  
Includes Tax filings and other Financial Data  
For Assistance Contact:  
Financial Regulation Section  
orinstax.ins@oregon.gov

**Drug Prices**

- 60-Day Increase Notice
- Annual Drug Price Filings
- New Specialty Drug Filings

**Manage Users**

**Application Information:**  
Drug Price reporting and correspondence by Pharmaceutical Manufacturers  
For Assistance Contact:  
Drug Price Transparency Program  
rx.prices@oregon.gov  
503-947-7200

**Save** **Cancel**

# 60-day price increase notice reporting

## When to file?

- Reporting threshold for **brand-name** drugs:
  - Planned increase of 10 percent or more within the 12-month period prior to the increase dateOR
  - A planned increase of \$10,000 or more.
- Reporting threshold for **generic** drugs:
  - Planned increase of 25 percent or more within the 12-month period prior to the increase dateAND
  - The increase is \$300 or more.



# 60-day price increase notice reporting


## When to file?

- Due date: If required, the report must be filed at least 60 days prior to the date of the planned increase.
- Exception: This report is not required if the drug is manufactured by four or more companies and meets the criteria listed in ORS 646A.683(4).




# 60-day price increase notice reporting

- Start 60-day price increase notice filing.
- Enter NDC and date of planned price increase.
  - Add new NDC and enter trade name and chemical name if not populated.



The screenshot shows a software interface with a navigation bar at the top containing 'New Drugs', 'Annual Filings', 'Correspondence', '60-Day', and 'Billings'. The '60-Day' tab is selected. On the left, there is a sidebar with 'Filings' and 'Details' options. The main content area features a 'Show All' dropdown menu, a '10 records per page' selector, and a table header with columns for 'Create/Filing Date', 'Trade Name', and 'NDC'. The table body is empty, displaying 'No data available' and 'Showing 0 to 0 of 0 entries'. A 'Create New Filing' button is located at the bottom of the table area.



The screenshot shows the '60-Day Price Increase Notice' form. It includes the following fields and controls:

- NDC:** Text input field containing '45678912300' with a red asterisk indicating it is required.
- Trade Name:** Text input field containing 'Brand name' with a red asterisk.
- Chemical Name:** Text input field containing 'Chemical name' with a red asterisk.
- Add New NDC:** A checked checkbox.
- Date Increase Effective:** Text input field containing '06/01/2023' with a calendar icon and a red asterisk.

At the bottom of the form, there are two buttons: 'Next' (highlighted in blue) and 'Cancel'.

# 60-day price increase notice reporting

- Complete the report following our user guide.

Name:


\* Year Available in US:

\* Current Price (WAC):

**Price Increase for this NDC**

\* New Price (WAC):

Trade Secret?  ▼

\* Date Increase Effective:  

Trade Secret?  ▼

# 60-day price increase notice reporting

- Complete the report following our user guide.

**Reason for Price Increase**

Change:    
 *A chemical change was made.*

Improvement:    
 *A functional improvement was made.*

\* Description:  Trade Secret?

Other:    
 *Use this when the price increase is due to reasons not identified above.*

Description:  Trade Secret?



If there was no change or improvement to the drug, remember to select “yes” for other reason and provide a description.

Other Relevant Information:  Trade Secret?



# Correspondence and requests for information



- Correspondence is a way to communicate directly with program staff members regarding a report in iReg.
- This can be used to communicate information or ask questions specific to that report.
- Respond to request for information (RFI) letters in iReg.



Note that iReg correspondence is published to the prescription drug price transparency website when the report status is marked “Filing Complete.”

# Correspondence and requests for information

- Correspondence thread for a report can be accessed at the bottom of the report.
- View message box and attachments posted by program staff.





# Correspondence and requests for information

- Correspondence tab lists all correspondence.
- Each thread is associated with a report.

The screenshot displays a web application interface for managing correspondence. At the top, there are navigation tabs: "New Drugs", "Annual Filings", "Correspondence" (which is active), "60-Day", and "Billings". To the right of these tabs are "Instructions" and "Log out" buttons. Below the navigation, there is a "Thread List" button and a "Details" section. The main content area features a "Show All" dropdown menu, a "10 records per page" selector, and a search bar. Below this is a table with the following columns: Start Date, Status, Filing Type, Trade Name, NDC, Rcvd/Sent/New, Attn Date, and Attn Party. The table contains three rows of data, all with a start date of 01/06/2022 and a status of Submitted. The first row is selected, indicated by a blue radio button. The table footer shows "Showing 1 to 3 of 3 entries" and navigation buttons for "Previous", "1", and "Next".

Start Date	Status	Filing Type	Trade Name	NDC	Rcvd/Sent/New	Attn Date	Attn Party
01/06/2022	Submitted	increase	Brand name, if applicable	00112233445	1 / 1 / 1		DFR
01/06/2022	Submitted	annual	Brand name, if applicable	00112233445	1 / 1 / 1		DFR
01/06/2022	Submitted	specialty	Brand name, if applicable	00112233445	0 / 1 / 0		DFR



# Correspondence and requests for information

- When responding, select “Add Correspondence.” Provide information in the message box. Attach a document, if needed.

Chemical Name:

---

01/06/2022 - parrase Other  
**Reply Due: 02/25/2022** Viewed On: 01/27/2023  
Message:

---

01/06/2022 - flastnax Request for Additional Information  
Message:  Viewed On: 01/06/2022

---

[Add Correspondence](#)

### New Correspondence

Correspondence Type:  \*

Message:  Trade Secret?

Supporting Document:  2022 public hearing written comments - emails.pdf Trade Secret?

# Correspondence and requests for information

## Tips and reminders:

- Review due dates for correspondence.
- Make sure your company is not delaying or rejecting emails from iReg (email addresses ending with .gov).
- Email [rx.prices@dcbs.oregon.gov](mailto:rx.prices@dcbs.oregon.gov) if you have questions about how to respond.
- Correspondence is not posted to the transparency site until the report status is set to “Filing Complete.”



# Trade secret claims and determinations

Is it a trade secret?

- Is the information *specific*?
- Is there company protocol for protecting the information?
- Is it available anywhere else?
- Is it kept as a secret?



# Trade secret claims and determinations

Examples that are not a trade secret:

- Generalized information that is not specific or detailed.
- Common industry knowledge or practice.
- Information available publicly, including anywhere on the web.
- Non-responsive entries such as “0” or “1” or “\$0” answers.
- iReg correspondence message box when only the document contains trade secrets.

# Trade secret claims and determinations

Before claiming trade secret, carefully review OAR 836-200-0540 (Information Claimed to be Trade Secret).

## *Steps when claiming trade secret:*

1. Clearly indicate or mark which information is asserted as trade secret.
2. For each piece of information, provide a written explanation that demonstrates all of the listed criteria.



# Trade secret claims and determinations

## *Steps when claiming trade secret (continued):*

3. The manufacturer has the burden of proof to establish that information submitted is conditionally exempt from disclosure as a trade secret.
4. Read the entire administrative rule and ORS 192.345.
5. Trade secret determinations are sent securely to contacts using Biscom. Keep contacts updated in iReg.



# Trade secret claims and determinations



## Common errors:

- Claiming a trade secret for information commonly shared outside the company, such as WAC or dosage.
- Listing common industry practices as trade secret.
- Listing the estimated average number of patients as a trade secret when it is from a source outside the company.
- Claiming public funds used for research and development as trade secret when funding is public information, or entering \$0 and claiming trade secret.

# Trade secret claims and determinations

## Tips and reminders:

- Reporting information *is* required even when claiming trade secret.
- Report and delineate the specific information that *is* a trade secret from information that is not.
- Burden of proof for trade secret claims is on the manufacturer.
- Do not send trade secret information using standard email.



# Billings and assessments

## Annual billing information

- Annual billing owed by all reporting manufacturers.
- Amount owed each year:
  - Annual assessment: Each reporting manufacturer owes this fee, currently set at \$400.
  - Reporting assessment: Manufacturers who submitted reports during the billing period owe a fee for each report. The amount varies each year.



# Billings and assessments

## Annual billing information

- Billing period: Aug. 1 of prior year through July 31 of current year.
  - 2023 billing period = Aug. 1, 2022, through July 31, 2023. Reporting assessment is based on new drug and annual increase reports filed during the period.
- Due date: **Oct. 1** each year.
  - 2023 annual billing is due **Oct. 1, 2023**.
- Demand to pay notice: Issued 30 days before due date.
  - Demand to pay notices will be sent via iReg Sept. 1, 2023.

# Billings and assessments

- View the Billings tab to see a list of each year's assessment.

Correspondence 60-Day Billings				
10 records per page				
	Year	Status	Amount Billed	Due Date
<input checked="" type="radio"/>	2022	COMPLETED	1187.00	10/01/2022
<input type="radio"/>	2021	COMPLETED	400.00	10/01/2021
<input type="radio"/>	2020	COMPLETED	1067.00	10/01/2020
<input type="radio"/>	2019	COMPLETED	6085.00	10/01/2019

Showing 1 to 4 of 4 entries



Notices about billings are usually sent through iReg and can be reviewed by viewing all contacts history in the Contacts tab.



# Billings and assessments

- Select “Details” to access the voucher and detailed information about the billing.

Year:	<input type="text" value="2020"/>
Billing Status:	<input type="text" value="PENDING"/> *
Annual Assessment Billed:	<input type="text" value="400.00"/> *
Report Assessment Billed:	<input type="text" value="93854.00"/> *
Total Amount Billed:	<input type="text" value="94254.00"/>
Due Date:	<input type="text" value="10/01/2020"/> *

10 records per page

10 records per page

NDC	Trade Name	Chemical Name	Filing Type
00002143461	p_trade_name	p_chemical_name	New Specialty
00002143461	p_trade_name	p_chemical_name	New Specialty
00002143461	p_trade_name	p_chemical_name	New Specialty
00002143461	p_trade_name	p_chemical_name	New Specialty
00002143461	p_trade_name	p_chemical_name	New Specialty
00002143461	p_trade_name	p_chemical_name	New Specialty
00002143461	p_trade_name	p_chemical_name	New Specialty
00002143461	p_trade_name	p_chemical_name	New Specialty
00002143461	p_trade_name	p_chemical_name	New Specialty
00002143461	p_trade_name	p_chemical_name	New Specialty

Showing 1 to 10 of 145 entries

← Previous

Print Payment Coupon



# Billings and assessments


- Select “Fiscal Details” to see the financial transactions.

Billing Year:


	Activity Date	Posting Type	Amount	Balance	Annual Assessment Credited	Annual Assessment Balance	Report Assessment Credited	Report Assessment Balance	Interest Credited	Interest Balance
<input checked="" type="radio"/>	03/22/2022	14	-4284.00	0.00	400.00	0.00	3884.00	0.00	0.00	0.00
<input type="radio"/>	03/18/2022	11	4284.00	4284.00	-400.00	400.00	-3884.00	3884.00	0.00	0.00

# Billings and assessments

- Debts sent to collections will not reflect the balance available from Accounts Receivable or the Department of Revenue.
- Voucher can no longer be printed from iReg, so contact us if you need a copy for your records.



Insurance iReg - Business Home    In Collections | Enforcement Action    4.0  
Entity Name: DRUG PRICE TEST CO.    User Name: First & Last Name  
Home    Drug Prices



New Drugs    Annual Filings    Correspondence    60-Day    **Billings**    Instructions    Log out

List    Details    Fiscal Details

10 records per page    Filter

	Year	Status	Amount Billed	Due Date
<input checked="" type="radio"/>	2021	IN COLLECTIONS (A.R.)	400.00	10/01/2021
<input type="radio"/>	2020	COMPLETED	400.00	10/01/2020
<input type="radio"/>	2019	COMPLETED	400.00	10/01/2019

Showing 1 to 3 of 3 entries    ← Previous    1    Next →

# Billings and assessments

## Tips and reminders:

- Make sure reports submitted are required.
- Check fiscal details for balances and payments posted.
- Include voucher when paying. Mail check payments as instructed on the voucher or call cashiering to pay by credit or debit card.
- Annual billings not paid by the due date will be sent to collections (our accounts receivable unit).
- For debts in collections, we can tell you who to contact for balance and payment options.



# Links and resources

Drug Price Transparency (DPT) contacts:

- ❖ Program email: [rx.prices@dcbs.oregon.gov](mailto:rx.prices@dcbs.oregon.gov); message line 503-947-7200 or 833-210-4560 (toll-free)
- ❖ Sofia Parra, program coordinator: [sofia.e.parra@dcbs.oregon.gov](mailto:sofia.e.parra@dcbs.oregon.gov); or call directly at 503-983-0447
- ❖ Sally Sylvester, compliance specialist: [sally.b.sylvester@dcbs.oregon.gov](mailto:sally.b.sylvester@dcbs.oregon.gov)
- ❖ Cashiering unit (credit or debit card payments): 503-947-7891; available 8 a.m. to 4 p.m. (Monday-Friday)
- iReg reporting system: <https://www4.cbs.state.or.us/exs/ins/ireg/>
- DPT webpage for manufacturers with information and user guide: <https://dfr.oregon.gov/drugtransparency/Pages/manufacturers.aspx>

# Links and resources

- DPT main webpage: <https://dfr.oregon.gov/drugtransparency/>
- Oregon Revised Statutes: ORS 646A.680 to 646A.692 (drug price transparency statutes). Click on link and scroll down to referenced statutes.  
[https://www.oregonlegislature.gov/bills\\_laws/ors/ors646A.html](https://www.oregonlegislature.gov/bills_laws/ors/ors646A.html)
- Oregon Administrative Rules: OAR 836-200-0500 through 836-200-0560. Click on link and scroll down to referenced rules.  
<https://secure.sos.state.or.us/oard/displayDivisionRules.action?selectedDivision=3795>
- Bulletin 2020-12: <https://dfr.oregon.gov/laws-rules/Documents/Bulletins/bulletin2020-12.pdf>
- Oregon Revised Statutes: ORS 192.345 (trade secret exemption).  
[https://www.oregonlegislature.gov/bills\\_laws/ors/ors192.html](https://www.oregonlegislature.gov/bills_laws/ors/ors192.html)



# Questions?

Contact DPT program at [rx.prices@dcbs.oregon.gov](mailto:rx.prices@dcbs.oregon.gov)  
or contact Sofia Parra (program coordinator) at  
[sofia.e.parra@dcbs.oregon.gov](mailto:sofia.e.parra@dcbs.oregon.gov) or 503-983-0447



Department of Consumer  
and Business Services